Kuehn Law Investigates Shareholder Claims in Proposed Mergers Involving ITI, RXRX, GVP, and OBDE

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Shareholder rights advocacy firm Kuehn Law, PLLC, has announced an investigation into potential legal claims stemming from proposed mergers involving several publicly-traded companies. These inquiries aim to ensure fair treatment and full disclosure for the shareholders of the respective companies in lieu of the forecasted business consolidations.

Investigation into Potential Claims

Kuehn Law is closely reviewing the details surrounding the proposed mergers concerning these companies:

• GVP - GSE Systems, Inc., a multinational corporation that offers an extensive array of professional engineering, software, and personnel services to the power and process industries.
• RXRX - Recursion Pharmaceuticals, Inc., noted for its pioneering approaches to drug discovery through the use of cutting-edge biology and data science.
• EXAI - Exscientia Limited, a frontrunner in employing artificial intelligence in the pharmaceutical sector, committed to accelerating drug discovery and development.
• ITI - Iteris, Inc., known for providing technological solutions targeted at intelligent transportation systems across North America and Europe.

In each case, Kuehn Law seeks to protect the interests of shareholders by possibly pushing for greater transparency or other forms of equitable remedies. The firm invites investors holding stocks in these companies to contact them to learn more about their rights and possible legal entitlements concerning the proposed mergers.

About the Companies Involved

GVP is based in Columbia, Maryland, and caters primarily to the power and process industries through its specialized engineering services and simulation solutions. The international presence of GSE Systems reflects its established expertise in this field.

RXRX, Recursion Pharmaceuticals, represents the forefront of biotechnological innovation by converging diverse scientific disciplines to revolutionize drug discovery. The Salt Lake City-based firm operates with a unique model that rapidly identifies potential novel treatments.

EXAI stands out for its dedication to advancing how drugs are discovered, utilizing the power of artificial intelligence to enhance the efficiency and effectiveness of its processes. The United Kingdom-based company continually strives for innovation in the pharmaceutical arena.

ITI, Iteris, Inc., headquartered in Santa Ana, California, supplies advanced systems and services designed to improve transportation infrastructure, with a firm presence in both the Canadian and European markets.

shareholder, legal, merger